Recommendations on the use of 18F-FDG PET in oncology

James Fletcher, Benjamin Djulbegovic, Heloisa P. Soares, Barry A. Siegel, Val J. Lowe, Gary H. Lyman, R. Edward Coleman, Richard Wahl, John Christopher Paschold, Norbert Avril, Lawrence Einhorn, W. Warren Suh, David Samson, Dominique Delbeke, Mark Gorman, Anthony F. Shields

Research output: Contribution to journalArticle

679 Citations (Scopus)

Abstract

The rationale was to develop recommendations on the use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor. Outcomes of interest included the use of 18F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer. Methods: A search was performed to identify all published randomized controlled trials and systematic reviews in the literature. An additional search was performed to identify relevant unpublished systematic reviews. These publications comprised both retrospective and prospective studies of varied methodologic quality. The anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and the impact of 18F-FDG PET on the management of cancer patients, were also reviewed. Results and Conclusion: 18F-FDG PET should be used as an imaging tool additional to conventional radiologic methods such as CT or MRI; any positive finding that could lead to a clinically significant change in patient management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results. 18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor. PET is also indicated for staging of breast, colon, esophageal, head and neck, and lung cancer and of lymphoma and melanoma. In addition, 18F-FDG PET should be used to detect recurrence of breast, colorectal, head and neck, or thyroid cancer and of lymphoma.

Original languageEnglish
Pages (from-to)480-508
Number of pages29
JournalJournal of Nuclear Medicine
Volume49
Issue number3
DOIs
StatePublished - Mar 1 2008

Fingerprint

Fluorodeoxyglucose F18
Head and Neck Neoplasms
Unknown Primary Neoplasms
Lymphoma
Lung Neoplasms
Breast
Pancreatic Neoplasms
Thyroid Neoplasms
Melanoma
Recurrence
Sarcoma
Publications
Neoplasms
Colon
Randomized Controlled Trials
Retrospective Studies
Prospective Studies

Keywords

  • F-FDG PET
  • Oncology
  • PET

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Fletcher, J., Djulbegovic, B., Soares, H. P., Siegel, B. A., Lowe, V. J., Lyman, G. H., ... Shields, A. F. (2008). Recommendations on the use of 18F-FDG PET in oncology. Journal of Nuclear Medicine, 49(3), 480-508. https://doi.org/10.2967/jnumed.107.047787

Recommendations on the use of 18F-FDG PET in oncology. / Fletcher, James; Djulbegovic, Benjamin; Soares, Heloisa P.; Siegel, Barry A.; Lowe, Val J.; Lyman, Gary H.; Coleman, R. Edward; Wahl, Richard; Paschold, John Christopher; Avril, Norbert; Einhorn, Lawrence; Suh, W. Warren; Samson, David; Delbeke, Dominique; Gorman, Mark; Shields, Anthony F.

In: Journal of Nuclear Medicine, Vol. 49, No. 3, 01.03.2008, p. 480-508.

Research output: Contribution to journalArticle

Fletcher, J, Djulbegovic, B, Soares, HP, Siegel, BA, Lowe, VJ, Lyman, GH, Coleman, RE, Wahl, R, Paschold, JC, Avril, N, Einhorn, L, Suh, WW, Samson, D, Delbeke, D, Gorman, M & Shields, AF 2008, 'Recommendations on the use of 18F-FDG PET in oncology', Journal of Nuclear Medicine, vol. 49, no. 3, pp. 480-508. https://doi.org/10.2967/jnumed.107.047787
Fletcher J, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH et al. Recommendations on the use of 18F-FDG PET in oncology. Journal of Nuclear Medicine. 2008 Mar 1;49(3):480-508. https://doi.org/10.2967/jnumed.107.047787
Fletcher, James ; Djulbegovic, Benjamin ; Soares, Heloisa P. ; Siegel, Barry A. ; Lowe, Val J. ; Lyman, Gary H. ; Coleman, R. Edward ; Wahl, Richard ; Paschold, John Christopher ; Avril, Norbert ; Einhorn, Lawrence ; Suh, W. Warren ; Samson, David ; Delbeke, Dominique ; Gorman, Mark ; Shields, Anthony F. / Recommendations on the use of 18F-FDG PET in oncology. In: Journal of Nuclear Medicine. 2008 ; Vol. 49, No. 3. pp. 480-508.
@article{ccc567ebc7784936b6652eb7c493378f,
title = "Recommendations on the use of 18F-FDG PET in oncology",
abstract = "The rationale was to develop recommendations on the use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor. Outcomes of interest included the use of 18F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer. Methods: A search was performed to identify all published randomized controlled trials and systematic reviews in the literature. An additional search was performed to identify relevant unpublished systematic reviews. These publications comprised both retrospective and prospective studies of varied methodologic quality. The anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and the impact of 18F-FDG PET on the management of cancer patients, were also reviewed. Results and Conclusion: 18F-FDG PET should be used as an imaging tool additional to conventional radiologic methods such as CT or MRI; any positive finding that could lead to a clinically significant change in patient management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results. 18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor. PET is also indicated for staging of breast, colon, esophageal, head and neck, and lung cancer and of lymphoma and melanoma. In addition, 18F-FDG PET should be used to detect recurrence of breast, colorectal, head and neck, or thyroid cancer and of lymphoma.",
keywords = "F-FDG PET, Oncology, PET",
author = "James Fletcher and Benjamin Djulbegovic and Soares, {Heloisa P.} and Siegel, {Barry A.} and Lowe, {Val J.} and Lyman, {Gary H.} and Coleman, {R. Edward} and Richard Wahl and Paschold, {John Christopher} and Norbert Avril and Lawrence Einhorn and Suh, {W. Warren} and David Samson and Dominique Delbeke and Mark Gorman and Shields, {Anthony F.}",
year = "2008",
month = "3",
day = "1",
doi = "10.2967/jnumed.107.047787",
language = "English",
volume = "49",
pages = "480--508",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

TY - JOUR

T1 - Recommendations on the use of 18F-FDG PET in oncology

AU - Fletcher, James

AU - Djulbegovic, Benjamin

AU - Soares, Heloisa P.

AU - Siegel, Barry A.

AU - Lowe, Val J.

AU - Lyman, Gary H.

AU - Coleman, R. Edward

AU - Wahl, Richard

AU - Paschold, John Christopher

AU - Avril, Norbert

AU - Einhorn, Lawrence

AU - Suh, W. Warren

AU - Samson, David

AU - Delbeke, Dominique

AU - Gorman, Mark

AU - Shields, Anthony F.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - The rationale was to develop recommendations on the use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor. Outcomes of interest included the use of 18F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer. Methods: A search was performed to identify all published randomized controlled trials and systematic reviews in the literature. An additional search was performed to identify relevant unpublished systematic reviews. These publications comprised both retrospective and prospective studies of varied methodologic quality. The anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and the impact of 18F-FDG PET on the management of cancer patients, were also reviewed. Results and Conclusion: 18F-FDG PET should be used as an imaging tool additional to conventional radiologic methods such as CT or MRI; any positive finding that could lead to a clinically significant change in patient management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results. 18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor. PET is also indicated for staging of breast, colon, esophageal, head and neck, and lung cancer and of lymphoma and melanoma. In addition, 18F-FDG PET should be used to detect recurrence of breast, colorectal, head and neck, or thyroid cancer and of lymphoma.

AB - The rationale was to develop recommendations on the use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor. Outcomes of interest included the use of 18F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer. Methods: A search was performed to identify all published randomized controlled trials and systematic reviews in the literature. An additional search was performed to identify relevant unpublished systematic reviews. These publications comprised both retrospective and prospective studies of varied methodologic quality. The anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and the impact of 18F-FDG PET on the management of cancer patients, were also reviewed. Results and Conclusion: 18F-FDG PET should be used as an imaging tool additional to conventional radiologic methods such as CT or MRI; any positive finding that could lead to a clinically significant change in patient management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results. 18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor. PET is also indicated for staging of breast, colon, esophageal, head and neck, and lung cancer and of lymphoma and melanoma. In addition, 18F-FDG PET should be used to detect recurrence of breast, colorectal, head and neck, or thyroid cancer and of lymphoma.

KW - F-FDG PET

KW - Oncology

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=40449093361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449093361&partnerID=8YFLogxK

U2 - 10.2967/jnumed.107.047787

DO - 10.2967/jnumed.107.047787

M3 - Article

C2 - 18287273

AN - SCOPUS:40449093361

VL - 49

SP - 480

EP - 508

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 3

ER -